Anaptysbio price to sales ratio ANAB

Market value divided by revenue over the last twelve months, since 2018.

Today, Oct 23, 2026: n/m; a quarter missing
8-year median: 25.2×
8-year range: 4.6× to 196×
Peer median: 1.9×

Anaptysbio's price to sales ratio can't be checked today: its revenue for Q4 FY26, the quarter to Jun 30, 2026, is missing from our data, so the twelve months it rests on can't be added up.

On the days it had one over the last 8 years, its median was 25.2×, from 4.6× in Aug 2025 to 196× in Dec 2022.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	6.3×	5.9×	10.8×
2025	8.2×	4.6×	11.3×
2024	6.9×	6.9×	46.0×
2023	38.1×	25.4×	171×
2022	196×	6.8×	196×
2021	7.8×	6.4×	53.5×
2020	32.7×	21.3×	87.7×
2019	90.9×	55.3×	138×
2018	185×	167×	192×

Against its peers

Companies in Drug Manufacturers - General nearest Anaptysbio's size, closest first, today.

Company	Price to sales ratio
ANABAnaptysbio	n/m
PCRXPacira BioSciences	1.9×
PAHCPhibro Animal Health	1.0×
ANIPANI Pharmaceuticals	1.7×
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	1.5×
HRMYHarmony Biosciences	2.2×
PBHPrestige Consumer Healthcare	2.0×
ABUSArbutus Biopharma	4.6×
NRIXNurix Therapeutics	3.9×
COLLCollegium Pharmaceutical	0.9×
Peer median	1.9×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Anaptysbio

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.